Table 3.
Change in clinical variables following treatment with RASi monotherapy vs. combination therapy with RASi and SGLT2i.
| RASi | RASi + SGLT2i | p | |
|---|---|---|---|
| eGFR (mL/min/1.73 m2) | −1.96 ± 12 | −0.27 ± 10 | 0.07 |
| UACR (mg/g) | 2.51 ± 165 | −7.56 ± 121 | 0.44 |
| Serum albumin (g/dL) | −0.04 ± 0.3 | 0.00 ± 0.4 | 0.16 |
| Hemoglobin (g/dL) | −0.06 ± 1.2 | 0.32 ± 1.6 | 0.001 |
| Serum potassium (mmol/L) | 0.06 ± 0.5 | −0.02 ± 0.4 | 0.05 |
| Serum triglycerides (mg/dL) | 4.36 ± 125 | 0.54 ± 113 | 0.71 |
| BMI (kg/m2) | 0.00 ± 1.5 | −0.53 ± 2.2 | <0.001 |
| Systolic BP (mmHg) | 0.05 ± 16.7 | −3.19 ± 14.5 | 0.02 |
| Diastolic BP (mmHg) | 0.06 ± 9.7 | −1.74 ± 8.8 | 0.02 |
| HbA1c (%) | 0.13 ± 1.0 | −0.24 ± 1.4 | <0.001 |
| C-reactive protein (mg/dL) | 0.01 ± 2.6 | 0.09 ± 2.1 | 0.72 |
| LDL cholesterol (mg/dL) | −1.72 ± 32.6 | −0.68 ± 40.7 | 0.77 |
| HDL cholesterol (mg/dL) | −0.36 ± 10.1 | 0.91 ± 8.2 | 0.12 |
Data are mean ± SD. UACR: urinary albumin-to-creatinine ratio; BP: blood pressure; RASi: renin–angiotensin system inhibitor; SGLT2i: sodium–glucose co-transporter 2 inhibitor.